Genome-scale CRISPR-Cas9 screen of Wnt/β-catenin signaling identifies therapeutic targets for colorectal cancer
Abstract
Genome-scale CRISPR screen identifies KMT2A as a druggable target against Wnt/β-catenin signaling and colorectal cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 21, 2021
- Source ID
- 10.1126/sciadv.abf2567
Entities
People
- Anh Doan
- Chunhua Wan
- Claire Sun
- Dakang Xu
- Danxi Zhu
- Dhanya Sooraj
- H. Chua
- Jia Bian
- Jolanta Grembecka
- Ron Firestein
- Sylvia Mahara
- Tomasz Cierpicki
- Yue Li
Organizations
- American Cancer Society
- American College of Surgeons
- Hudson Institute of Medical Research
- Monash University
- National Health and Medical Research Council
- Shanghai Jiao Tong University
- University of Michigan
- University of Oxford